Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Baxter
Johnson and Johnson
Mallinckrodt
Colorcon

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ASN002

See Plans and Pricing

« Back to Dashboard

What is the drug development status for ASN002?

ASN002 is an investigational drug.

There have been 7 clinical trials for ASN002. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2018.

The most common disease conditions in clinical trials are Eczema, Dermatitis, and Dermatitis, Atopic. The leading clinical trial sponsors are Asana BioSciences and [disabled in preview].

There are four US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for ASN002
TitleSponsorPhase
Phase 2 Study to Evaluate ASN002 in Subjects With Severe Chronic Hand EczemaAsana BioSciencesPhase 2
Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male SubjectsAsana BioSciencesPhase 1
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisAsana BioSciencesPhase 2

See all ASN002 clinical trials

Clinical Trial Summary for ASN002

Top disease conditions for ASN002
Top clinical trial sponsors for ASN002

See all ASN002 clinical trials

US Patents for ASN002

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASN002   Start Trial Pyrimido-pyridazinone compounds and methods of use thereof Asana BioSciences, LLC (Lawrenceville, NJ)   Start Trial
ASN002   Start Trial Uses of pyrimido-pyridazinones to treat cancer Asana BioSciences, LLC (Lawrenceville, NJ)   Start Trial
ASN002   Start Trial Pyrimido-pyridazinone compounds and methods of use thereof Endo Pharmaceuticals Inc. (Malvern, PA)   Start Trial
ASN002   Start Trial Pyrimido-pyridazinone compounds and methods of use thereof Asana Biosciences, LLC (Bridgewater, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASN002

Drugname Country Document Number Estimated Expiration Related US Patent
ASN002 Brazil 112014003981 2031-08-23   Start Trial
ASN002 Canada 2846187 2031-08-23   Start Trial
ASN002 China 103974955 2031-08-23   Start Trial
ASN002 China 108707151 2031-08-23   Start Trial
ASN002 Denmark 2748166 2031-08-23   Start Trial
ASN002 European Patent Office 2748166 2031-08-23   Start Trial
ASN002 European Patent Office 3392252 2031-08-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Baxter
McKinsey
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.